Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in Azenta, Inc. $AZTA

Universal Beteiligungs und Servicegesellschaft mbH lessened its position in Azenta, Inc. (NASDAQ:AZTA) by 32.6% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 36,761 shares of the company’s stock after selling 17,790 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Azenta were worth $1,132,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AZTA. Mechanics Financial Corp raised its stake in Azenta by 77.6% in the 2nd quarter. Mechanics Financial Corp now owns 870 shares of the company’s stock valued at $27,000 after purchasing an additional 380 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Azenta by 41.6% in the second quarter. Farther Finance Advisors LLC now owns 1,371 shares of the company’s stock valued at $42,000 after buying an additional 403 shares during the last quarter. CWM LLC raised its position in shares of Azenta by 113.5% in the second quarter. CWM LLC now owns 1,898 shares of the company’s stock valued at $58,000 after buying an additional 1,009 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Azenta by 29.1% in the second quarter. Allworth Financial LP now owns 2,050 shares of the company’s stock worth $63,000 after buying an additional 462 shares in the last quarter. Finally, State of Wyoming boosted its position in Azenta by 77.1% during the first quarter. State of Wyoming now owns 2,343 shares of the company’s stock worth $81,000 after acquiring an additional 1,020 shares during the last quarter. 99.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on AZTA shares. Needham & Company LLC increased their price objective on shares of Azenta from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Azenta in a report on Monday. Zacks Research downgraded Azenta from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Jefferies Financial Group raised shares of Azenta from a “hold” rating to a “buy” rating and upped their target price for the company from $30.00 to $38.00 in a research report on Thursday, October 30th. Finally, Raymond James Financial lifted their price target on shares of Azenta from $35.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $38.60.

Azenta Stock Down 4.8%

Azenta stock opened at $36.27 on Thursday. Azenta, Inc. has a 52-week low of $23.91 and a 52-week high of $55.63. The firm has a market cap of $1.66 billion, a PE ratio of -14.99 and a beta of 1.65. The company’s 50 day moving average is $31.09 and its two-hundred day moving average is $30.53.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Friday, November 21st. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The company had revenue of $159.19 million for the quarter, compared to analyst estimates of $156.76 million. During the same quarter last year, the company earned $0.18 EPS. Azenta’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, equities research analysts anticipate that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.